MUC1 and systemic sclerosis: Kumánovics and colleagues measured serum KL-6 levels at baseline and 9 ± 22 months later in 158 patients with SSc and found that KL-6 levels decreased in 31 patients with SSc-ILD who were treated with CYC independent of the improvement or deterioration of their PFT parameters [17].